By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Exela Pharma
Sciences, LLC v. EKR Therapeutics, LLC et al.
5:13-cv-00111;
filed August 8, 2013 in the Western District of North Carolina

• Plaintiff: 
Exela Pharma Sciences, LLC
• Defendants: 
EKR Therapeutics, LLC; Cornerstone Therapeutics Inc.; Cornerstone BioPharma,
Inc.

Declaratory
judgment of non-infringement and invalidity of U.S. Patent No. 7,659,290 ("Methods
of Preparing Pre-Mixed, Ready-to-Use Pharmaceutical Compositions," issued
February 9, 2010) based on Exela's filing of a supplemental NDA (under §
505(b)(2) of the Food, Drug and Cosmetic Act) to manufacture a generic version
of EKR's Cardene® I.V. Premixed Injection (nicardipine hydrochloride premixed
injection for intravenous administration, used for the short-term treatment of
hypertension when oral therapy is not feasible or not desirable).  View the complaint here.

Pfizer Inc.
et al. v. Wockhardt Bio AG et al.
1:13-cv-01387;
filed August 2, 2013 in the District Court of Delaware

• Plaintiffs: 
Pfizer Inc.; UCB Pharma GmbH
• Defendants: 
Wockhardt Bio AG; Wockhardt USA LLC

Infringement
of U.S. Patent Nos. 6,858,650 ("Stable Salts of Novel Derivatives of
3,3-Diphenylpropylamines," issued February 22, 2005), 7,384,980 ("Derivatives
of 3,3-Diphenylpropylamines," issued June 10, 2008), 7,855,230 (same
title, issued December 21, 2010), 7,985,772 (same title, issued July 26, 2011),
and 8,338,478 (same title, issued December 25, 2012) following a Paragraph IV
certification as part of Wockhardt's filing of an ANDA to manufacture a generic
version of Pfizer's Toviaz® (fesoterodine fumarate, used to treat the symptoms
of overactive bladder).  View the
complaint here.

Novartis
Pharmaceuticals Corp. v. Hospira, Inc.
2:13-cv-04669;
filed August 2, 2013 in the District Court of New Jersey

Infringement
of U.S. Patent Nos. 7,932,241 ("Pharmaceutical Products Comprising
Bisphosphonates," issued April 26, 2011) and 8,324,189 ("Use of
Zolendronate for the Manufacture of a Medicament for the Treatment of Bone
Metabolism Diseases," issued December 4, 2012) following a Paragraph IV
certification as part of Hospira's filing of an ANDA and an NDA (under §
505(b)(2) of the Food, Drug and Cosmetic Act) 
to manufacture a generic versions of Novartis' Zometa® (zoledronic acid,
used for the prevention of skeletal-related complications associated with
cancer).  View the complaint here.

Repros
Therapeutics Inc. v. Fisch
4:13-cv-02266;
filed August 2, 2013 in the Southern District of Texas

Declaratory
judgment of ownership and inventorship for U.S. Patent Nos. 7,173,064 ("Methods
and Compositions with Trans-Clomiphene for Treating Wasting and Lipodystrophy,"
issued February 6, 2007), 7,368,480 ("Methods and Compositions with
Trans-Clomiphene), 7,737,185 (same title, issued June 15, 2010) and 7,759,360 ("Methods
and Materials for the Treatment of Testosterone Deficiency in Men," issued
July 20, 2010), relating to Repros' pipeline drug Androxal®(trans-isomer of clomiphene
citrate, to be used for the treatment of male secondary hypogonadism).  View the complaint here.